LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

(RTTNews) - Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by ...

(RTTNews) - Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments. Kura ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to ...

(RTTNews) - Several biotechnology and pharmaceutical names posted notable gains in after-hours trading on Monday, driven by clinical trial updates, regulatory progress, and investor anticipation ahead ...

(RTTNews) - Biotech stocks saw notable upward momentum in Thursday's after-hours trading session, with several names posting strong percentage gains despite the absence of fresh company-specific ...

Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, ...

CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...

The average one-year price target for Rossari Biotech (BSE:543213) has been revised to ₹ 652.81 / share. This is a decrease of 21.25% from the prior estimate of ₹ 828.92 dated December 20, 2025. The ...